SIAwinner
commented on
$SIA (C6L.SG)$ Is this price worth it?
Translated
1
1
SIAwinner
commented on
$SIA (C6L.SG)$ important week. QR week.
pray for huge dividend...20 - 35cents...anything extra is SUPER BONUS
pray for huge dividend...20 - 35cents...anything extra is SUPER BONUS
2
3
SIAwinner
commented on
$SIA Engineering (S59.SG)$
SIA Engineering has reported full-year FY2025 earnings of $139.6 million, up 43.8% y-o-y. For the 2HFY2024/25, the company reported earnings of $70.8 million, up 87.3% y-o-y.
The group posted a revenue for the FY2025 of $1.245 billion, up 13.8% y-o-y, supported by stable growth in demand for aircraft maintenance, repair and overhaul (MRO) services.
Final ordinary dividend : 7 cents
$SIA (C6L.SG)$
SIA Engineering has reported full-year FY2025 earnings of $139.6 million, up 43.8% y-o-y. For the 2HFY2024/25, the company reported earnings of $70.8 million, up 87.3% y-o-y.
The group posted a revenue for the FY2025 of $1.245 billion, up 13.8% y-o-y, supported by stable growth in demand for aircraft maintenance, repair and overhaul (MRO) services.
Final ordinary dividend : 7 cents
$SIA (C6L.SG)$
4
1
SIAwinner
liked
$SIA (C6L.SG)$Bill Gate in SG, what is the motive behind? One of the YouTuber analyse, do you agree with him? - YouTube
2
1
SIAwinner
liked


4
SIAwinner
commented on
$Tharimmune (THAR.US)$ Garbage.
Translated
1
SIAwinner
liked
$Tharimmune (THAR.US)$
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Monday, 28th April at 8:01 am
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (NASDAQ: THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug A...
3
SIAwinner : yes. buy before 15/05